The present invention relates to fatty acid-grafted hyaluronic acid (FA-g-HA), and a sterile microsphere-based dermal filler formulation and a sterile crosslinked hyaluronic acid-based dermal filler formulation each comprising the FA-g-HA. The present invention further relates to processes for the preparation of the FA-g-HA and the dermal filler formulations comprising the FA-g-HA, and their use in cosmetic applications.

A sterile hydrogel composition that includes a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of a thiol-modified hyaluronan and wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of more than about 80 μmol per gram polymer, wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of less than about 280 μmol per gram polymer, and wherein the thiol-modified hyaluronan has a mean molecular weight of at least 400 kDa.

The disclosed technology provides thermoplastic polyurethane compositions having antimicrobial properties while still maintaining good physical properties and good non-fouling properties, methods of making the same, and articles, including medical devices, made from such compositions. The disclosed technology includes a process of making an antimicrobial polymer composition, where the process includes mixing an antimicrobial additive into a base polymer and further includes mixing in a non-fouling additive, where the antimicrobial additive is chemically held in the composition and the antimicrobial and non-fouling additives do not negatively impact each other's effectiveness.

The present disclosure relates to a novel sericin-based hydrogel wherein the silk sericin is enzymatically cross-linked for an improved treatment of wound healing, ischemic diseases or cardiovascular diseases, namely chronic wound healing, in particular diabetic wound.

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising:

(A) at least one taurinamide derivative,

(B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof; and

(C) heparin at a low concentration.

The present invention relates to the contacting of one or more surfaces of an implantable medical device with one or more diketopiperazines (DKPs).

A method for inhibiting biofilm formation by bacteria on a surface or disrupting existing biofilm on a surface, including contacting the surface or existing biofilm with 2-(indolin-2-yl)-1H-ind, di(1H-indol-3-yl)methane and 1,1′-biindole, or any combination thereof.

Described herein are formulations that transition from a liquid state to a solid state for use in the embolization of arteriovenous malformations (AVM's) and solid tumors.

The present disclosure provides a biomaterial and a method for promoting tissue regeneration by using the biomaterial.